

Form 1449*	Atty. Docket No.: 295.022US1	Serial No. Unknown 08/927,937
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicants: David J. Grainger et al.	
	Filing Date: Herewith 9/11/97	Group: Unknown 08/927,937

1646

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PM	5,202,118	04/13/1993	Gillis, et al.	424	85.2	05/06/91
↓	5,212,073	05/18/1993	Rollins, et al.	435	69.5	05/12/89
↓	5,401,651	03/28/1995	Walz	435	240.2	10/16/91
↓	5,650,150	07/22/1997	Gillies	424	134.1	07/27/94

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes   No
PM	90/07863	07/26/1990	PCT	<del>C07K</del>	<del>7/10</del>	
↓	92/20372	11/26/1992	PCT	A61K	37/66	
↓	93/11159	06/10/1993	PCT	<del>C07K</del>	<del>13/00</del>	

## OTHER DOCUMENTS


(Including Author, Title, Date, Pertinent Pages, Etc.)

PM	Arenzana-Seisdedos, F., et al., "HIV Blocked by Chemokine Antagonists", <u>Nature</u> , 383, 400, (Oct. 3, 1996)
PM	Clark-Lewis, I., et al., "Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids", <u>J. Biol. Chem.</u> , 269, 16075-16081, (June 10, 1994)
PM	Cocchi, F., et al., "Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ as the Major HIV-Suppressive Factors Produced by CD8 <sup>+</sup> T Cells", <u>Science</u> , 270, 1811-1815, (Dec. 15, 1995)
PM	Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", <u>Nature</u> , 368, 744-745 (Apr. 21, 1994)
PM	Lusti-Narasimhan, M., et al., "A Molecular Switch of Chemokine Receptor Selectivity", <u>J. Biol. Chem.</u> , 271, 3148-3153, (Feb. 9, 1996)
PM	Yahi, N., et al., "SPC3, a Synthetic Peptide Derived from the V3 Domain of Human Immunodeficiency Virus Type 1 (HIV-1) gp120, Inhibits HIV-1 Entry into CD4 <sup>+</sup> and CD4 <sup>-</sup> Cells by Two Distinct Mechanisms", <u>Natl. Acad. Sci. USA</u> , 92, 4867-4871, (May 1995)
PM	Zhang, Y., et al., "A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer", <u>Mol. and Cell Biol.</u> , 15, 4851-4855, (Sept. 1995)
PM	Zhang, Y., et al., "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis", <u>J. Biol. Chem.</u> , 269, 15918-15924 (1994)

Examiner: <u>Premas Menz</u>	Date Considered: <u>3/26/99</u>
------------------------------	---------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 4

Form 1449\*

Atty. Docket No.: 295.022US1

Serial No. 08/927,939

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1997

Group: 1646  
1801

## U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PM	4,724,232	02/09/1988	Rideout et al.	514	50	09/17/95
	5,079,228	01/07/1992	Cohen et al.	514	12	02/05/90
	5,302,384	04/12/1994	Gimbrone, Jr. et al.	424	85.2	02/25/93
	5,458,874	10/17/1995	Pereira et al.	424	85.1	10/30/92
	5,459,128	10/17/1995	Rollins et al.	514	8	10/27/94
	5,474,983	12/12/1995	Kuna et al.	514	12	03/15/93
	5,556,757	09/17/1996	Alstyne et al.	435	7.2	06/07/95
	5,571,713	11/05/1996	Lyle et al.	435	240.2	05/27/94
	5,578,714	11/26/1996	Pogo et al.	536	23.5	10/21/93
	5,605,671	02/25/1997	Lyle et al.	424	1.41	04/29/94
	5,627,156	05/06/1997	Talmadge	514	13	09/23/94
	5,646,117	07/08/1997	Matsushima et al.	514	12	03/25/95
	5,661,132	08/26/1997	Eriksson et al.	514	44	11/22/94
	5,705,360	01/06/1998	Rollins et al.	435	69.1	07/16/96
	5,707,814	01/13/1998	Levy et al.	435	7.1	03/05/96
	5,707,815	01/13/1998	Charo et al.	435	7.2	05/25/95

## FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes   No
PM	9-255570 A	03/21/1996	Japan	A61K	031/35	With Abstract
	91/08483	06/13/1991	PCT	G01N	33/53	
	92/04372	03/19/1992	PCT	C07K	7/00	
	96/22371	07/25/1996	PCT	C12N	15/12	
	97/12615	04/10/1997	PCT	A61K	31/425	
	97/21812	06/19/1997	PCT	C12N	15/19	
	97/22698	06/26/1997	PCT	C12N	15/12	
	97/25427	07/17/1997	PCT	C12N	15/19	
	97/29192	08/14/1997	PCT	C12N	15/19	
	97/31098	08/28/1997	PCT	C12N	1/20	
	97/32019	09/04/1997	PCT	C12N	15/12	

RECEIVED  
SEP 22 1999  
GROUP 1800

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
PM	"Blocking CCR5 Stops M-tropic HIV Infection", <u>Biotechnology News</u> , 17, 3 (1997)
PM	Buckley, C.D., "Treatment of Rheumatoid Arthritis", <u>BMJ</u> , 315, 236-238 (July 26, 1997)
PM	Clark-Lewis, I., et al., "Platelet Factor 4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg", <u>Proceedings of the National Academy of Sciences, USA</u> , 90, 3574-3577, (1993)

Examiner


Prema Menz

Date Considered

3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 5

Form 1449\*

App. Docket No.: 295.022US1

Serial No. 08/927,939

## INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1997

Group: 1801 1646

RECEIVED

SEP 22 1999

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

GROUP 1800

PM

Clark-Lewis, I., et al., "Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs", The Journal of Biological Chemistry, 266, 23128-23134, (1991)

Drazen, J.M., et al., "Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway", Int. Arch. Allergy Immunol., 107, 319-320 (1995)

Gong, J.-H., et al., "An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-*lpr* Mouse Model", J. Exp. Med., 186, 131-137 (July 7, 1997)

Grossman, J., et al., "Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist", Journal of Asthma, 34, 321-328 (1997)

Hauser, S.L., "Therapeutic Strategies for Multiple Sclerosis", J. Neurochem., 69, Suppl., Abstract A, p. S219 (1997)

Hendeles, L., et al., "Zafirlukast for Chronic Asthma: Convenient and Generally Safe, But Is It Effective?", The Annals of Pharmacotherapy, 31, 1084-1086 (Sep. 1997)

Hilliquin, P., et al., "Treatment of Rheumatoid Arthritis with Platelet Activating Factor Antagonist BN 50730", J. Rheumatol., 22, 1651-1654 (1995)

Hogan, S.P., et al., "Cytokines as Targets for the Inhibition of Eosinophilic Inflammation", Pharmacol. Ther., 74, 259-283 (1997)

Hunter, M.G., et al., "BB-10010: An Active Variant of Human Macrophage Inflammatory Protein-1 $\alpha$  with Improved Pharmaceutical Properties" Blood, 86, 4400-4408 (Dec. 15, 1995)

Ishikawa, J., et al., "Effect of YM934, a Novel Potassium-Channel Opener, in Various Experimental Asthma Models in Guinea-pigs", J. Pharm. Pharmacol., 48, 1034-1040 (1996)

Israel, E., et al., "Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma", JAMA, 275, 931-936 (Mar. 27, 1996)

Katz, M.D., et al., "Octreotide, a New Somatostatin Analogue", Clinical Pharmacy, 8, 255-273 (Apr. 1989)

Examiner


Prenna Muntz

Date Considered

3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 4 of 5

Form 1449\*

Atty. Docket No.: 295.022US1

Serial No. 08/927,939

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1997

Group: 1804646

RECEIVED

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

SEP 22 1999

GROUP 1800

PM

Klareskog, L., et al., "Immunopathogenesis and Immunotherapy in Rheumatoid Arthritis: an Area in Transition", Journal of Internal Medicine, 238, 191-206 (1995)

Kledel, T.N., et al., "A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus", Science, 277, 1656-1659 (Sep. 12, 1997)

Leong, S.R., et al., "Complete Mutagenesis of the Extracellular Domain of Interleukin-8 (IL-8) Type A Receptor Identifies Charged Residues Mediating IL-8 Binding and Signal Transduction", Journal of Biological Chemistry, 19343-19348, (1994)

Lowe, P.M., et al., "The Endothelium in Psoriasis", British Journal of Dermatology, 132, 497-505 (1995)

Malkowski, M.G., et al., "The Crystal Structure of Recombinant Human Neutrophil-Activating Peptide-2 (M6L) at 1.9-Å Resolution", The Journal of Biological Chemistry, 270, 7077-7087 (Mar. 31, 1995)

Miller, E.J., et al., "A Synthetic Peptide which Specifically Inhibits Heat-Treated Interleukin-8 Binding and Chemotaxis for Neutrophils", Agents Actions, 40, 200-208 (1993)

Mölling, K., "Naked DNA for Vaccine or Therapy", J. Mol. Med., 75, 242-246 (1997)

Moser, B., et al., "Interleukin-8 Antagonists Generated by N-Terminal Modification", The Journal of Biological Chemistry, 268, 7125-7128 (1993)

Myers, L.K., et al., "Collagen-Induced Arthritis, an Animal Model of Autoimmunity", Life Sciences, 61, 1861-1878 (1997)

Plater-Zyberk, C., et al., "Effect of a CC Chemokine Receptor Antagonist on Collagen Induced Arthritis in DBA/1 Mice", Immunology Letters, 57, 117-120 (1997)

Reiss, T.F., et al., "Effects of Montelukast (MK-0476), a New Potent Cysteinyl Leukotriene (LTD<sub>4</sub>) Receptor Antagonist, in Patients with Chronic Asthma", J. Allergy Clin. Immunol., 98, 528-534 (Sep. 1996)

Simmons, G., et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist", Science, 276, 276-279 (Apr. 11, 1997)

Examiner


Prenna Menly

Date Considered

3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 5 of 5

Form 1449\*

Atty. Docket No.: 295.022US1

Serial No. 08/927,939

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1997

Group: ~~1801~~ 1646

RECEIVED

SEP 22 1999

GROUP 1800

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

PM	Smith, L.J., et al., "Inhibition of Leukotriene D <sub>4</sub> -Induced Bronchoconstriction in Subjects With Asthma: A Concentration-Effect Study of ICI 204,219", <u>Clin. Pharmacol. Ther.</u> , 54, 430-436 (1993)
	Spector, S.L., "Leukotriene Activity Modulation in Asthma", <u>Drugs</u> , 54, 369-384 (Sep. 1997)
	Spector, S.L., et al., "Effects of 6 Weeks of Therapy with Oral Doses of ICI 204,219, a Leukotriene D <sub>4</sub> Receptor Antagonist, in Subjects with Bronchial Asthma", <u>Am. J. Respir. Crit. Care Med.</u> , 150, 618-623 (1994)
	Suissa, S., et al., "Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma", <u>Ann. Intern. Med.</u> , 126, 177-183 (1997)
	Tamura, G., et al., "Effect of a Potent Platelet-Activating Factor Antagonist, WEB-2086, on Asthma", In: <u>Platelet-Activating Factor and Related Lipid Mediators</u> , 2, Nigam, et al., (eds.), Plenum Press, New York, 371-380 (1996)
	Valente, A.J., et al., "Characterization of Monocyte Chemotactic Protein-1 Binding to Human Monocytes", <u>Biochemical and Biophysical Research Communications</u> , 176, 309-314 (Apr. 15, 1991)
	Weber, M., et al., "Deletion of the NH <sub>2</sub> -Terminal Residue Converts Monocyte Chemotactic Protein 1 from an Activator of Basophil Mediator Release to an Eosinophil Chemoattractant", <u>J. Exp. Med.</u> , 183, 681-685 (Feb. 1996)
	Wells, T.N.C., et al., "The Molecular Basis of Selectivity Between CC and CXC Chemokines: The Possibility of Chemokine Antagonists as Anti-Inflammatory Agents", <u>Annals of the New York Academy of Sciences</u> , 796, 245-257 (Oct. 31, 1996)
	Wells, T.N.C., et al., "The Molecular Basis of the Chemokine/Chemokine Receptor Interaction -- Scope for Design of Chemokine Antagonists", <u>Methods: A Companion to Methods in Enzymology</u> , 10, 126-134 (1996)
✓	Wooley, P.H., et al., "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice", <u>The Journal of Immunology</u> , 151, 6602-6607 (Dec. 1, 1993)

Examiner

Prenn Mentz

Date Considered

3/28/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.